Ongoing Disclosure Notice

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
AFT Pharmaceuticals Limited (AFT)
Date this disclosure made:
13-Dec-18
Date of last disclosure:
22-Au
g-18
Director or senior mana
ger giving disclosure
Full name(s):
David Flacks
Name of listed issuer:
AFT Pharmaceuticals Limited (AFT)
Name of related body corporate (if applicable):
Not applicable
Position held in listed issuer:
Director
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected
quoted financial products:
Full
y-Paid Ordinary Shares in AFT
Nature of the affected relevant interest(s):
Joint re
gistered holder and beneficial owner of ordinary
shares
For that relevant interest-
Number held in class before ac
quisition or disposal:
115,431
Number held in class after ac
quisition or disposal:
145,431
Current re
gistered holder(s):
Unknown
Registered holder(s) once transfers are registered:
David Mark Flacks & Adina Rita Bett
y Halpern as trustees of
Waitemata Family Trust
Details of transactions
giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1
Details of transactions requiring disclosure-
Date of transaction:
12-Dec-18
Nature of transaction: On-market acquisition of ordinar
y shares
Name of any other party or parties to the transaction (if known)Unknown
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal
If the consideration was not in cash and cannot be readily by converted into a cash value, describe
the consideration:NZ$2.1967 per share / $65,901.00
Number of financial products to which the transaction related:
30,000
If the issuer has a financial products trading policy that prohibits directors or senior managers from
trading during any period without written clearance (a closed period) include the following details—
Whether relevant interests were acquired or disposed of durin
g a closed periodNo
Whether prior written clearance was provided to allow the acquisition or disposal to proceed durin
g
the closed period:
Not applicable
Date of the
prior written clearance (if any):
Not applicable
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products
:Not applicable
Nature of relevant interest:Not applicable
For that relevant interest,-
Number held in class:Not applicabl
e
Current registered holder(s):Not applicable
For a derivative relevant interest,-
Type of derivative:Not applicable
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial products (if
any):
Not applicable
A statement as to whether the derivative is cash settled or physically settled
Not applicable
Maturity date of the derivative (if any):
Not applicable
Expiry date of the derivative (if any):
Not applicable
The price's specified terms (if any):
Not applicabl
e
Any other details needed to understand how the amount of the consideration payable under the
derivative or the value of the derivative is affected by the value of the underlying financial products:
Not applicable
For that derivative relevant interest,-
Parties to the derivative:
Not applicabl
e
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in
the derivative:
Not applicable
Certification
I certif
y that, to the best of my knowledge and belief, the information contained in this disclosure is
correct and that I am duly authorised to make this disclosure by all persons for whom it is made.
Signature of director or officer:
Date of si
gnature:13-Dec-18